These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11983946)

  • 1. Optimized combination of antiplatelet treatment and anticoagulation for percutaneous coronary intervention: the final word is not out yet!
    Gruberg L; Beyar R
    J Invasive Cardiol; 2002 May; 14(5):251-3. PubMed ID: 11983946
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges of antiplatelet therapy in patients who require anticoagulation.
    Henkel DM; Holmes DR
    J Invasive Cardiol; 2009 Apr; 21(4):186-9. PubMed ID: 19342758
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting.
    Zinn A; Feit F
    Am J Cardiol; 2009 Sep; 104(5 Suppl):49C-54C. PubMed ID: 19695362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation.
    Rubboli A; Colletta M; Di Pasquale G
    Am Heart J; 2005 Feb; 149(2):E1. PubMed ID: 15846242
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
    Helft G; Gilard M; Le Feuvre C; Zaman AG
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):673-80. PubMed ID: 17122800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.
    Kelly RV; Steinhubl S
    Heart; 2005 Jun; 91 Suppl 3(Suppl 3):iii16-9. PubMed ID: 15919646
    [No Abstract]   [Full Text] [Related]  

  • 7. The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
    D'Agate DJ; Patel S; Coppola JT; Ambrose JA
    J Invasive Cardiol; 2004 Sep; 16(9):500-3. PubMed ID: 15353833
    [No Abstract]   [Full Text] [Related]  

  • 8. Hazard--the anticoagulation bridge or just go transradial.
    Gilchrist IC
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):48-9. PubMed ID: 19089937
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]).
    Gilard M; Blanchard D; Helft G; Carrier D; Eltchaninoff H; Belle L; Finet G; Le Breton H; Boschat J;
    Am J Cardiol; 2009 Aug; 104(3):338-42. PubMed ID: 19616664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying drug-eluting stents in clinical practice.
    King SB
    Am J Cardiol; 2007 Sep; 100(5A):25K-31K. PubMed ID: 17719350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous coronary artery dissection and the role for percutaneous coronary intervention: to treat or not to treat?
    Chue CD; Routledge HC; Townend JN
    J Invasive Cardiol; 2009 Mar; 21(3):E44-7. PubMed ID: 19258650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Percutaneous coronary intervention].
    Csapó K
    Orv Hetil; 2005 Mar; 146(13):587-93. PubMed ID: 15856622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
    Karjalainen PP; Porela P; Ylitalo A; Vikman S; Nyman K; Vaittinen MA; Airaksinen TJ; Niemelä M; Vahlberg T; Airaksinen KE
    Eur Heart J; 2007 Mar; 28(6):726-32. PubMed ID: 17267456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ
    Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The search for optimal combination of antiplatelet and anticoagulation regimens following PCI.
    Gruberg L; Beyar R
    J Invasive Cardiol; 2003 May; 15(5):240-1. PubMed ID: 12730629
    [No Abstract]   [Full Text] [Related]  

  • 18. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
    Roffi M; Topol EJ
    Eur Heart J; 2004 Feb; 25(3):190-8. PubMed ID: 14972418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
    Maegdefessel L; Schlitt A; Faerber J; Bond SP; Messow CM; Buerke M; Raaz U; Werdan K; Muenzel T; Weiss C
    Med Klin (Munich); 2008 Sep; 103(9):628-32. PubMed ID: 18813885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landmarks: examining the foundation for GP IIb/IIIa inhibitors in PCI.
    J Invasive Cardiol; 2002 Dec; 14(12):776-9. PubMed ID: 12537005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.